Poison Prevention Packaging Requirements; Exemption of Powder Formulations of Colesevelam Hydrochloride and Sevelamer Carbonate

Consumer Product Safety Commission · 2011

Read Poison Prevention Packaging Requirements; Exemption of Powder Formulations of Colesevelam Hydrochloride and Sevelamer Carbonate by Consumer Product Safety Commission (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-18511.txt.

Description

Rule published in the Federal Register on 2011-07-22 by Consumer Product Safety Commission. Text from federalregister.gov (official edition: govinfo). [Pages 43847-43851] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-18511] ======================================================================= ----------------------------------------------------------------------- CONSUMER PRODUCT SAFETY COMMISSION 16 CFR Part 1700 [CPSC Docket No. CPSC-2011-0007] Poison Prevention Packaging Requirements; Exemption of Powder Formulations of Colesevelam Hydrochloride and Sevelamer Carbonate AGENCY: Consumer Product Safety Commission. ACTION: Final rule.

Catalog record

CREATORConsumer Product Safety Commission
YEAR2011
COLLECTIONLAW
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSEPublic Domain
RIGHTSPUBLIC DOMAIN
SOURCEFederal Register

Source: https://www.federalregister.gov/documents/2011/07/22/2011-18511/poison-prevention-packaging-requirements-exemption-of-powder-formulations-of-colesevelam

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Poison Prevention Packaging Requirements; Exemption of Powder Formulations of Colesevelam Hydrochloride and Sevelamer Carbonate Citation: us:fr:2011-18511 Creator: Consumer Product Safety Commission Year: 2011 Source-URL: https://www.federalregister.gov/documents/2011/07/22/2011-18511/poison-prevention-packaging-requirements-exemption-of-powder-formulations-of-colesevelam Context: Rule published in the Federal Register on 2011-07-22 by Consumer Product Safety Commission. Text from federalregister.gov (official edition: govinfo). [Pages 43847-43851] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-18511] ======================================================================= ----------------------------------------------------------------------- CONSUMER PRODUCT SAFETY COMMISSION 16 CFR Part 1700 [CPSC Docket No. CPSC-2011-0007] Poison Prevention Packaging Requirements; Exemption of Powder Formulations of Colesevelam Hydrochloride and Sevelamer Carbonate AGENCY: Consumer Product Safety Commission. ACTION: Final rule. ----------------------------------------------------------------------- SUMMARY: The Consumer Product Safety Commission (``CPSC,'' ``Commission,'' or ``we'') is amending its child-resistant packaging requirements to exempt powder formulations of two oral prescription drugs, colesevelam hydrochloride and sevelamer carbonate. Colesevelam hydrochloride, currently marketed as Welchol [supreg], is available in a powder formulation and is indicated to reduce elevated LDL cholesterol levels and improve glycemic control in adults with type 2 diabetes mellitus. Sevelamer carbonate, currently marketed as Renvela [supreg], is also available as a powder formulation and is indicated for the control of elevated serum phosphorus in chronic kidney disease patients on dialysis. The rule exempts these [[Page 43848]] prescription drug products on the basis that child-resistant packaging is not needed to protect young children from serious injury or illness from powder formulations of colesevelam hydrochloride and sevelamer carbonate because the products are not acutely toxic, lack adverse human experience associated with acute ingestion, and, in powder form, are not likely to be ingested in large quantities by children under 5 years of age. DATES: The rule becomes effective on July 22, 2011. FOR FURTHER INFORMATION CONTACT: John Boja, Office of Compliance, Consumer Product Safety Commission, Bethesda, MD 20814-4408; telephone (301) 504-7300; [email protected]. SUPPLEMENTARY INFORMATION: A. Background 1. The Poison Prevention Packaging Act of 1970 and Implementing Regulations The Poison Prevention Packaging Act of 1970 (``PPPA''), 15 U.S.C. 1471-1476, gives the Commission authority to establish standards for the ``special packaging'' of household substances, such as drugs, when child-resistant (``CR'') packaging is necessary to protect children from serious personal injury or illness due to the substance and the special packaging is technically feasible, practicable, and appropriate for such substance. Accordingly, CPSC regulations require that oral prescription drugs be in CR packaging. 16 CFR 1700.14(a)(10). The powder forms of cholestyramine and colestipol, two drugs that are chemically similar to colesevelam hydrochloride and sevelamer carbonate, currently are exempt from CR packaging. Id. 1700.14(a)(10)(v) and (xv). CPSC regulations allow companies to petition the Commission for exemption from CR requirements. 16 CFR part 1702. Among the possible grounds for granting an exemption are that: The degree or nature of the hazard to children in the availability of the substance, by reason of its packaging, is such that special packaging is not required to protect children from serious personal injury or serious illness resulting from handling, using or ingesting the substance. 16 CFR 1702.17. 2. The Products for Which Exemptions Are Sought a. Welchol [supreg] (Colesevelam Hydrochloride) On February 24, 2009, Daiichi Sankyo, Inc. (``Daiichi'') petitioned the Commission to exempt the powdered form of colesevelam hydrochloride, which it markets as Welchol [supreg], from the special packaging requirements for oral prescription drugs. The petitioner stated that the exemption is justified because of lack of toxicity and lack of adverse human experience with the drug. Welchol [supreg] has been marketed in tablet form and dispensed in CR packaging. On October 2, 2009, the U.S. Food and Drug Administration (``FDA'') approved a new powder formulation of the drug. The petition requested an exemption only for the powder dosage form of Welchol [supreg]. The product, in tablet form, would continue to be in CR packaging. Welchol [supreg] is a bile acid sequestrant indicated as an adjunct to: (1) Reduce elevated low-density lipoprotein cholesterol (LDL-C) levels; and (2) improve glycemic control in adults with type 2 diabetes mellitus. The new dosage form of Welchol [supreg] provides 1.875 g or 3.75 g of the powdered drug in unit dose packages to be mixed with water and taken orally as a suspension. (A unit dose package of Welchol [supreg] is a pouch that contains an individual dose.) b. Renvela [supreg] (Sevelamer Carbonate) On March 6, 2009, Genzyme Corporation (``Genzyme'') petitioned the Commission to exempt the powdered form of sevelamer carbonate, which it markets as Renvela, [supreg] from the special packaging requirements for oral prescription drugs. The petitioner stated that the exemption is justified because of lack of toxicity and lack of adverse human experience with the drug. Renvela [supreg] is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. The tablets are marketed with a pill crusher for patients who have trouble swallowing the tablets. The company reformulated Renvela [supreg] as a powder to be taken as an oral suspension, and the FDA approved this powder formulation on August 12, 2009. The new dosage form of Renvela [supreg] provides either 0.8 g or 2.4 g of Renvela [supreg] powder in unit dose packages to be mixed with 2 ounces of water. B. Proposed Rule On February 16, 2011, we published a notice of proposed rulemaking (``NPR'') proposing to exempt from special packaging the powder forms of colesevelam hydrochloride (Welchol [supreg]) and sevelamer carbonate (Renvela [supreg]). 76 FR 8942. As explained in the preamble to the proposed rule, we considered the two exemption petitions together because Welchol [supreg] and Renvela [supreg] have similar chemical structures, biological properties, and powder formulations. C. Toxicity and Human Experience Data 1. Summary of Data From Proposed Rule As noted in the preamble to the proposed rule (76 FR at 8943), the systemic toxicity of colesevelam hydrochloride and sevelamer carbonate is limited because they are not absorbed from the gastrointestinal (GI) tract. There is no data indicating that either drug is acutely toxic. Acute toxicity is the type of toxicity that is of concern when considering whether CR packaging is appropriate. Even in patients taking these drugs chronically, the adverse effects are mostly minor, such as diarrhea, nausea, constipation, flatulence, and dyspepsia. If a child were to ingest accidentally Welchol [supreg] or Renvela [supreg], the potential for the occurrence of mild to moderate GI discomfort, such as indigestion, constipation, nausea, and vomiting does exist. However, a review of relevant data indicates that an acute ingestion of these drugs would not result in serious toxicity. CPSC's CR packaging regulations exempt cholestyramine and colestipol in powder form, two bile acid sequestrants that are similar chemically to Welchol [supreg] and Renvela.[supreg] We have not found any relevant articles in the medical literature describing toxic effects following the acute ingestion of either cholestyramine or colestipol from 1975 through 2010. As discussed in the preamble to the proposed rule (76 FR at 8944), we searched the following databases for incidents related to Welchol [supreg] and Renvela [supreg] occurring between 2000 and 2009: the Injury and Potential Injury Incident database (``IPII''), the National Electronic Injury Surveillance System database (``NEISS''), and the Death Certificates database (``DTHS''). We found one incident involving Welchol [supreg] in the NEISS database. In that incident, 11-month-old twin boys were taken to the emergency room after they had been playing with their

Read the complete text